Dysbiosis success triggers further investment and development agreement for additional microbiome tests beyond GA-map™ dysbiosis Test

(Oslo and Hercules, Calif.) Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed a supply and distribution agreement for Genetic Analysis’s GA-map™ clinical test for gut dysbiosis.

The patented GA-map™ technology is used as an aide in the diagnosis and management of irritable bowel syndrome and inflammatory bowel disease.

Dysbiosis is a microbial imbalance or maladaptation on or inside the body and is most commonly reported as a condition in the digestive tract. It has been associated with illnesses, such as inflammatory bowel disease and other chronic diseases.

“We are delighted to enter into this agreement with Bio-Rad,” said Ronny Hermansen, CEO of Genetic Analysis. “During the past year, the body of evidence supporting the use of GA-map™has grown considerably. Bio-Rad has the market knowledge and necessary resources to accelerate the uptake of this technology by clinicians worldwide. We look forward to further developing our product portfolio with Bio-Rad’s continuing support.”

“We welcome the opportunity to partner with Genetic Analysis,” said John Hertia, Bio-Rad Executive Vice President, President, Clinical Diagnostics Group.  “With the GA-map technology, we will be able to offer products that can analyze the microbiome associated with gut dysbiosis, which affects the quality of life of many patients around the world and can result in serious health problems.”